Skip to main content

Table 2 Study endpoints at 6 weeks

From: Empagliflozin prevents doxorubicin-induced myocardial dysfunction

  Controls DOX group DOX + EMPA group DOX + FURO group
Weight, g 23.18 ± 1.8 21.45 ± 2.7 22.5 ± 2.1 21.8 ± 2.4
Glucose, mg/dl 200.6 ± 40 166.6 ± 72 205.5 ± 39 170.5 ± 50
Systolic pressure, mmHg 121 ± 15 102 ± 37 119 ± 20* 105 ± 33
Diastolic pressure, mmHg 76 ± 11 41 ± 10 65 ± 28* 60 ± 24*
LVEF, % 68.7 ± 5% 49.24 ± 8 61.30 ± 11* 55.79 ± 11
LVFS, % 39.4 ± 3% 24.70 ± 5 33.08 ± 8* 28.62 ± 8
LVEDd, mm 3.11 ± 0.1 3.98 ± 0.4 3.89 ± 0.3 3.80 ± 0.7
LVESd, mm 1.93 ± 0.5 2.98 ± 0.4 2.67 ± 0.5 2.73 ± 0.5
IVS, mm 0.81 ± 0.001 0.69 ± 0.004 0.77 ± 0.001* 0.77 ± 0.005*
PW, mm 0.78 ± 0.001 0.71 ± 0.005 0.76 ± 0.013 0.76 ± 0.014
Longitudinal strain (LS),% − 24.1 ± 4% − 13.93 ± 5 − 17.52 ± 3* − 16.1 ± 3.5
Circumferential strain (CS), % − 29.9 ± 8% − 15.91 ± 6 − 25.75 ± 6* − 15.8 ± 3.3
Radial strain (RS), % 46.0 ± 7% 26.7 ± 13 24.0 ± 5 26.1 ± 4
E/A 1.6 ± 0.1 1.7 ± 0.2 1.6 ± 0.2 1.5 ± 0.1
E/Eʹ 41.1 ± 2.2 77.3 ± 3.5 61.1 ± 5.7* 59.4 ± 4*
  1. Values are mean ± SD, or n (%)
  2. LVEF left ventricular ejection fraction, LVFS left ventricular fractional shortening, IVS interventricular septum, PW posterior wall
  3. *p < 0.05 compared to DOX